Medical technology company Hologic has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for US $205 million.
This is subject to regulatory approvals and other conditions. Under the agreement terms, approximately 825 employees will transfer with the Cynosure business. “We are excited about the future for Cynosure with this recent announcement,” said Erik Anderson, division president of Cynosure.
He added, “Our business was strengthened under Hologic, and this new acquisition will accelerate our growth via expanded sales and marketing efforts along with further investments in innovation and new products which will support our customer partners and improve clinical outcomes for consumers.”